<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccine</journal-id><journal-id journal-id-type="iso-abbrev">Vaccine</journal-id><journal-title-group><journal-title>Vaccine</journal-title></journal-title-group><issn pub-type="ppub">0264-410X</issn><issn pub-type="epub">1873-2518</issn><publisher><publisher-name>Elsevier Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25173484</article-id><article-id pub-id-type="pmc">4414927</article-id><article-id pub-id-type="publisher-id">S0264-410X(14)01157-8</article-id><article-id pub-id-type="doi">10.1016/j.vaccine.2014.08.034</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>PedVacc 002: A phase I/II randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-positive mothers in Nairobi</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Njuguna</surname><given-names>Irene N.</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Ambler</surname><given-names>Gwen</given-names></name><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Reilly</surname><given-names>Marie</given-names></name><xref rid="aff0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Ondondo</surname><given-names>Beatrice</given-names></name><xref rid="aff0020" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Kanyugo</surname><given-names>Mercy</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Lohman-Payne</surname><given-names>Barbara</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Gichuhi</surname><given-names>Christine</given-names></name><xref rid="aff0025" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>Borthwick</surname><given-names>Nicola</given-names></name><xref rid="aff0020" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Black</surname><given-names>Antony</given-names></name><xref rid="aff0020" ref-type="aff">d</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author"><name><surname>Mehedi</surname><given-names>Shams-Rony</given-names></name><xref rid="aff0030" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Jiyu</given-names></name><xref rid="aff0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Maleche-Obimbo</surname><given-names>Elizabeth</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Chohan</surname><given-names>Bhavna</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>John-Stewart</surname><given-names>Grace C.</given-names></name><xref rid="aff0035" ref-type="aff">g</xref></contrib><contrib contrib-type="author"><name><surname>Jaoko</surname><given-names>Walter</given-names></name><xref rid="aff0040" ref-type="aff">h</xref></contrib><contrib contrib-type="author"><name><surname>Hanke</surname><given-names>Tom&#x000e1;&#x00161;</given-names></name><email>tomas.hanke@ndm.ox.ac.uk</email><xref rid="aff0020" ref-type="aff">d</xref><xref rid="aff0045" ref-type="aff">i</xref><xref rid="cor0005" ref-type="corresp">&#x0204e;</xref></contrib></contrib-group><aff id="aff0005"><label>a</label>Department of Pediatrics and Child Health, University of Nairobi, PO Box 19676, 00202 Nairobi, Kenya</aff><aff id="aff0010"><label>b</label>Department of Global Health, University of Washington, Seattle, WA 98104, USA</aff><aff id="aff0015"><label>c</label>Department of Medical Epidemiology and Biostatistics, Karolinska Institute, SE-17177 Stockholm, Sweden</aff><aff id="aff0020"><label>d</label>The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK</aff><aff id="aff0025"><label>e</label>Department of Clinical Medicine and Therapeutics, University of Nairobi, PO Box 19676, 00202 Nairobi, Kenya</aff><aff id="aff0030"><label>f</label>Statistics and Data Management Department, Medical Research Council Unit, Fajara, The Gambia</aff><aff id="aff0035"><label>g</label>Departments of Pediatrics, Medicine, Epidemiology, and Global Health, University of Washington, Seattle, WA 98104, USA</aff><aff id="aff0040"><label>h</label>KAVI-Institute of Clinical Research, University of Nairobi, PO Box 19676, 00202 Nairobi, Kenya</aff><aff id="aff0045"><label>i</label>The Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK</aff><author-notes><corresp id="cor0005"><label>&#x0204e;</label>Corresponding author at: The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK. Tel.: +44 0 1865 617630; fax: +44 0 1865 617608. <email>tomas.hanke@ndm.ox.ac.uk</email></corresp><fn id="fn1"><label>1</label><p>Present address: Institut Pasteur du Laos, Samsenthai Rd, Ban Kao-gnot, PO Box 3560, Vientiane, Lao Democratic People's Republic.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>07</day><month>10</month><year>2014</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="ppub">.--><pub-date pub-type="ppub"><day>07</day><month>10</month><year>2014</year></pub-date><volume>32</volume><issue>44</issue><fpage>5801</fpage><lpage>5808</lpage><history><date date-type="received"><day>5</day><month>6</month><year>2014</year></date><date date-type="rev-recd"><day>7</day><month>8</month><year>2014</year></date><date date-type="accepted"><day>15</day><month>8</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; 2014 The Authors</copyright-statement><copyright-year>2014</copyright-year><license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract abstract-type="author-highlights"><title>Highlights</title><p><list list-type="simple"><list-item id="lsti0005"><label>&#x02022;</label><p>MVA.HIVA vaccine was tested for the first time in HIV-1-exposed infants in Africa.</p></list-item><list-item id="lsti0010"><label>&#x02022;</label><p>PedVacc 002 had 99% retention of infants over 48 weeks of follow-up.</p></list-item><list-item id="lsti0015"><label>&#x02022;</label><p>MVA.HIVA was safe, but not sufficiently immunogenic.</p></list-item><list-item id="lsti0020"><label>&#x02022;</label><p>MVA.HVA did not interfere with routine childhood vaccines except for induction of HBV antibodies.</p></list-item><list-item id="lsti0025"><label>&#x02022;</label><p>MVA is well suited as a vaccine vector for infants under 1 year of age.</p></list-item></list></p></abstract><abstract><sec><title>Background</title><p>A safe, effective vaccine for breastfeeding infants born to HIV-1-positive mothers could complement antiretroviral therapy (ART) for prevention of mother-to-child transmission of HIV-1. To date, only a few HIV-1 vaccine candidates have been tested in infants.</p></sec><sec><title>Trial design</title><p>A phase I/II randomized controlled trial PedVacc 002 was conducted to determine the safety and immunogenicity of a single, low dose of MVA.HIVA vaccine delivered intramuscularly to healthy 20-week-old infants born to HIV-1-positive mothers in Nairobi, Kenya.</p></sec><sec><title>Methods</title><p>Pregnant HIV-1-positive women in the 2nd/3rd trimester of gestation were enrolled, provided with ART and self-selected their infant-feeding modality. Infants received nevirapine and cotrimoxazole prophylaxis. At 20 weeks of age, eligible HIV-1-negative infants were randomized to vaccine versus no-treatment arms and followed to 48 weeks of age for assessments of vaccine safety, HIV-1-specific T-cell responses and antibodies to routine childhood vaccines.</p></sec><sec><title>Results</title><p>Between February and November 2010, 182 mothers were screened, 104 were eligible and followed on ART during pregnancy/postpartum, of whom 73 had eligible infants at 20 weeks postpartum. Thirty-six infants were randomized to vaccine and 37 to no treatment. Eighty-four percent of infants breastfed, and retention at 48 weeks was 99%. Adverse events were rare and similar between the two arms. HIV-1-specific T-cell frequencies in interferon-&#x003b3; ELISPOT assay were transiently higher in the MVA.HIVA arm (<italic>p</italic>&#x000a0;=&#x000a0;0.002), but not above the threshold for a positive assay. Protective antibody levels were adequate and similar between arms for all routine childhood vaccines except HBV, where 71% of MVA.HIVA subjects compared to 92% of control subjects were protected (<italic>p</italic>&#x000a0;=&#x000a0;0.05).</p></sec><sec><title>Conclusions</title><p>This trial tested for the first time an MVA-vectored candidate HIV-1 vaccine in HIV-1-exposed infants in Africa, demonstrating trial feasibility and vaccine safety, low immunogenicity, and compatibility with routine childhood vaccinations. These results are reassuring for use of the MVA vector in more potent prime-boost regimens.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Modified vaccinia virus Ankara (MVA)</kwd><kwd>Infant vaccine trial in Africa</kwd><kwd>Exposed-uninfected infants</kwd><kwd>HIV-1</kwd><kwd>Pediatric HIV-1 vaccines</kwd><kwd>KEPI vaccines</kwd><kwd>EPI vaccines</kwd></kwd-group><kwd-group><title>Abbreviations</title><kwd>rMVA, recombinant modified vaccinia virus Ankara</kwd><kwd>HIV-1, human immunodeficiency virus type 1</kwd><kwd>HEU, HIV-1-exposed uninfected</kwd><kwd>ART, antiretroviral therapy</kwd><kwd>PMTCT, prevention of mother-to-child transmission of HIV-1</kwd><kwd>ZDV, zidovudine</kwd><kwd>TDF, tenofovir</kwd><kwd>3TC, lamivudine</kwd><kwd>LPV/RTV, lopinavir/ritonavir</kwd><kwd>EFV, efavirenz</kwd><kwd>NVP, nevirapine</kwd><kwd>HBV, hepatitis B virus</kwd><kwd>OPV, oral polio vaccine</kwd><kwd>KEPI, Kenyan Expanded Program on Immunization</kwd><kwd>Dtx, diphtheria toxin</kwd><kwd>Ttx, tetanus toxin (Ttx)</kwd><kwd>Hib, <italic>Hemophilus influenzae</italic> type b</kwd><kwd>KNH, Kenyatta National Hospital</kwd><kwd>IQR, interquartile range</kwd><kwd>WAZ, weight-for-age Z-score</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec0005"><label>1</label><title>Introduction</title><p>In 2012, an estimated 260,000 children became infected with the human immunodeficiency virus type 1 (HIV-1) (<ext-link ext-link-type="uri" xlink:href="http://www.unaids.org/" id="intr0005">www.unaids.org</ext-link>), the majority of whom acquired the virus from their mothers. The UNAIDS's ambitious <italic>Global Plan towards The Elimination of New HIV-1 Infections among Children by 2015 and Keeping Their Mothers Alive</italic> aims to decrease the number of new pediatric infections by 90% (<ext-link ext-link-type="uri" xlink:href="http://www.unaids.org/" id="intr0010">www.unaids.org</ext-link>). Although the Global Plan is well underway, only an estimated 57% of HIV-1-positive pregnant women in low- and middle-income countries accessed appropriate prevention of mother-to-child HIV-1 transmission (PMTCT) antiretroviral regimens in 2012. Incomplete access to antiretroviral therapy (ART), ART side effects <xref rid="bib0005 bib0010 bib0015 bib0020 bib0025 bib0030 bib0035 bib0040" ref-type="bibr">[1&#x02013;8]</xref>, non-adherence and/or HIV-1 drug resistance can lead to persistent risk of mother-to-child HIV-1 transmission despite expansion of PMTCT programs. Thus, effective HIV-1 vaccines to protect infants against breast milk HIV-1 transmission may complement and enhance current PMTCT strategies.</p><p>Vaccine prevention of breast milk HIV-1 transmission will require the priming vaccine to be administered within the first few days after birth, followed by boost(s) soon after. To date, there have been over 650 clinical studies assessing candidate HIV-1 vaccines in humans. However, fewer than 10 of these studies tested HIV-1 vaccine safety and immunogenicity in infants (<ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/" id="intr0015">www.clinicaltrials.gov</ext-link>), despite major differences in natural HIV-1 infection <xref rid="bib0045" ref-type="bibr">[9]</xref> and responsiveness to vaccinations <xref rid="bib0050 bib0055" ref-type="bibr">[10,11]</xref> between adults and infants/young children. Infants have distinct characteristics that may influence their response to HIV-1 vaccines. Despite evidence of infants&#x02019; lower capacity for some immune responses, they have some potential advantages for generating responses. For example, infants have fewer competing memory T-cell clones that exist at the time of vaccination, making &#x02018;space&#x02019; to establish new long-term cellular memory <xref rid="bib0060" ref-type="bibr">[12]</xref>. Thus, testing of candidate vaccines in pediatric populations is important for appropriate development of vaccines early in the pipeline <xref rid="bib0065" ref-type="bibr">[13]</xref>.</p><p>One of the leading boosting vectors for genetic subunit vaccines is modified vaccinia virus Ankara (MVA), known for its excellent safety and immunogenicity record from human trials involving several thousands of individuals <xref rid="bib0070" ref-type="bibr">[14]</xref>. As an inroad for MVA-vectored HIV-1 vaccine use in infants, we tested a low dose of vaccine MVA.HIVA <xref rid="bib0075" ref-type="bibr">[15]</xref> in parallel in infants born to HIV-1-negative mothers (PedVacc 001 trial in The Gambia) and in infants born to HIV-1-positive mothers (PedVacc 002 trial in Kenya). MVA.HIVA delivered the first ever immunogen derived from an African clade A HIV-1 <xref rid="bib0080" ref-type="bibr">[16]</xref> to reach human evaluation in Africa.</p><p>When the PedVacc 001 and 002 trials were conceived in 2007, only three studies of active immunization in infants were published. These other studies evaluated 3 <italic>Env</italic>-derived subunit proteins and 3 canarypoxvirus (ALVAC)-vectored vaccines in Pediatric AIDS Clinical Trials Group protocols (PACTG) 320 <xref rid="bib0085 bib0090 bib0095" ref-type="bibr">[17&#x02013;19]</xref> and 326 <xref rid="bib0100 bib0105" ref-type="bibr">[20,21]</xref> and HIV Pediatric Trials Network (HPTN) protocol 027 <xref rid="bib0110" ref-type="bibr">[22]</xref>. The tested ALVAC and protein vaccines caused no increase in serious adverse events (SAE) and elicited promising immune responses similar to those observed in adults. We recently reported that the PedVacc 001 trial had excellent safety and marginal immunogenicity among 20-week-old Gambian infants born to HIV-1-negative mothers <xref rid="bib0115" ref-type="bibr">[23]</xref>. Here, we report on the administration of MVA.HIVA to infants born to HIV-1-positive mothers in Kenya (PedVacc 002) with the primary aim to assess its safety. This was the first time that a rMVA vaccine with an HIV-1-derived transgene was administered to infants born to HIV-1-positive mothers.</p></sec><sec sec-type="materials|methods" id="sec0010"><label>2</label><title>Materials and methods</title><sec id="sec0015"><label>2.1</label><title>Study design</title><p>The Pediatric Vaccine (PedVacc) 002 study was a single-site, phase I/II, open, randomized, controlled trial of candidate HIV-1 vaccine MVA.HIVA compared to no treatment. The primary outcome was MVA.HIVA vaccine safety.</p></sec><sec id="sec0020"><label>2.2</label><title>Ethics and regulatory approvals</title><p>Approvals to conduct the study were granted by the Pharmacy and Poisons Board, Ministry of Medical Services, Kenya (ref. PPB/ECCT/08/25-2/10), Kenyatta National Hospital (KNH)/University of Nairobi Research Ethics Committee (ref. P266/10/2008), Nairobi University Institutional Biosafety Committee (ref. UON/CHS/PRINC/ADM1/SC6/IBC.CTTE/13), Oxford Tropical Research Ethics Committee (ref. OXTREC 52-08), University of Washington Institutional review Board (ref. HSD 35079), and the Stockholm Regional Ethics Committee (ref. 2009/1591-31/1). The study was conducted according to the principles of the Declaration of Helsinki (2008) and complied with the International Conference on Harmonization Good Clinical Practice guidelines.</p></sec><sec id="sec0025"><label>2.3</label><title>Study population</title><p>The study was conducted at KNH in Nairobi, Kenya. HIV-1-positive pregnant women in their 2nd/3rd trimester were recruited from antenatal clinics at KNH and Nairobi City Council clinics. Women were eligible to participate if they were aged 18 years or above, had CD4<sup>+</sup> cell count greater than 350&#x000a0;&#x003bc;l<sup>&#x02212;1</sup>, WHO stage 1 or 2 disease, planned to deliver at KNH, and planned to remain in the Nairobi area for one year after delivery. Women in the study gave written informed consent and the infant's father, or other family member or significant person co-signed the consent form for participation. Mothers were provided with ART for PMTCT as per WHO Option B guidelines consisting of zidovudine (ZDV) or tenofovir (TDF), lamivudine (3TC), and lopinavir/ritonavir (LPV/RTV) or efavirenz (EFV) or nevirapine (NVP) during pregnancy, delivery and throughout breastfeeding. Women were counseled on feeding options and provided formula milk if they elected to use replacement feeding.</p><p>Within 3 days of birth, singleton infants were enrolled if they weighed at least 2.5&#x000a0;kg and did not have congenital defects or underlying disease that might compromise evaluation of response to the candidate vaccine. Infants received NVP prophylaxis for the first 6 weeks of life and cotrimoxazole prophylaxis from 6 weeks of age. Breastfeeding infants continued cotrimoxazole throughout the breastfeeding period while formula-fed infants stopped at 10 weeks if their 6-week HIV-1 test was negative. Infants received Kenyan Expanded Program on Immunization (KEPI) vaccinations, which included BCG and oral poliovirus vaccine (OPV) at birth, OPV and Pentavalent vaccine (diphtheria toxin [Dtx], tetanus toxin [Ttx], whole cell pertussis [Ptx], <italic>Hemophilus influenzae</italic> type b [Hib] and hepatitis B virus [HBV] surface antigen [HBsAg]) at 6, 10 and 14 weeks of age. Pneumoccocal conjugate vaccine 10, introduced in the course of the study was administered to infants at variable ages. During study visits, a standard questionnaire on infant health and immunization was completed. At 20 weeks, infants were randomized if they had received all scheduled KEPI vaccines, were HIV-1-uninfected, had weight-for-age <italic>Z</italic>-scores no more than 2 standard deviations below normal, had no acute or chronic disease, had no history of anaphylaxis reaction to prior vaccination, and baseline laboratory investigations were within normal ranges.</p></sec><sec id="sec0030"><label>2.4</label><title>The study vaccine and its administration</title><p>MVA.HIVA is a recombinant non-replicating poxvirus, which carries the HIVA transgene inserted into the thymidine kinase locus of the parental MVA genome under the early/late P7.5 promoter <xref rid="bib0080" ref-type="bibr">[16]</xref>. MVA.HIVA was manufactured under current Good Manufacturing Practice conditions by IDT, Germany. It was provided in vials of 200&#x000a0;&#x003bc;l at 5&#x000a0;&#x000d7;&#x000a0;10<sup>8</sup> plaque-forming units (PFU)&#x000a0;ml<sup>&#x02212;1</sup> in 10&#x000a0;mM Tris&#x02013;HCl buffer pH 7.7 and 0.9% NaCl, and stored at &#x02264;&#x02212;20&#x000a0;&#x000b0;C. On the day of administration, each vial was thawed at room temperature and given within 1&#x000a0;h of thawing. Infants randomized to vaccine group received a single intramuscular dose of 5&#x000a0;&#x000d7;&#x000a0;10<sup>7</sup>&#x000a0;pfu of MVA.HIVA, while the control group received no treatment. Vaccinated infants were observed in the clinic for 1&#x000a0;h post-vaccination and visited at home after 24 and 48&#x000a0;h to assess for adverse reactions.</p></sec><sec id="sec0035"><label>2.5</label><title>Participant follow-up and safety monitoring</title><p>Randomization was generated at Karolinska Institute using a blocked design and participants were assigned using sealed envelopes. After randomization, medical history and examinations were conducted at 21, 28, 36 and 48 weeks of age. At 21 and 28 weeks, hematology and biochemistry tests were done as described below. Local, systemic and laboratory AEs, and relationship to MVA.HIVA were graded as per Clinical Protocol (Supplementary Information). Palpable lymph nodes, redness and induration were scored according to their diameters. Any Grade 3 or 4 laboratory AE was confirmed by re-test. An internal trial safety monitor reviewed Grade 3 and 4 events in real time and these were reported to the KNH Research Ethics committee. Study procedures were reviewed regularly by an external monitor. An external Data Monitoring and Ethics Committee reviewed safety data at 6-monthly intervals.</p></sec><sec id="sec0040"><label>2.6</label><title>Blood sampling schedule and handling</title><p>Laboratory personnel were blind to group allocation. Five ml of blood (4&#x000a0;ml EDTA, 1&#x000a0;ml clotted) was collected at 19, 21, 28, 36 and 48 weeks of age. MVA.HIVA immunogenicity was tested at all 5 time points; hematology, biochemistry (including alanine transaminase [ALT] and creatinine tests), and CD4<sup>+</sup> cell counts were conducted at 19, 21 and 28 weeks. KEPI vaccine antibody responses were determined at 19 and 21 weeks. HIV-1 testing was performed using HIV-1 DNA PCR at birth, 6, 10, 14 and 20 weeks; HIV-1 viral load at 19, 28, 36 and 48 weeks and HIV-ELISA at 48 weeks. Peripheral blood mononuclear cells (PBMC) were isolated and used for interferon (IFN)-&#x003b3; ELISPOT assays or frozen <xref rid="bib0115" ref-type="bibr">[23]</xref>.</p></sec><sec id="sec0045"><label>2.7</label><title>IFN-&#x003b3; ELISPOT assay</title><p>Fresh <italic>ex vivo</italic> and cultured IFN-&#x003b3; ELISPOT assays were carried out as previously described <xref rid="bib0115" ref-type="bibr">[23]</xref>. An assay failed quality control if the mean background was &#x0003e;20 spot-forming units (SFU)/well (&#x0003e;100 SFU/10<sup>6</sup> PBMC) or mean phytohemagglutinine response was &#x0003c;30 SFU/well (&#x0003c;150 SFU/10<sup>6</sup> PBMC). A response was considered positive if the mean stimulated response was at least twice the mean background response and the net response (with background subtracted) was &#x02265;50 SFU/10<sup>6</sup> PBMC.</p></sec><sec id="sec0050"><label>2.8</label><title>KEPI vaccine antibody responses</title><p>Microsphere-based multiplex assays were performed at the National Institute for Public Health and the Environment, Bilthoven, The Netherlands to quantify serum IgG antibodies against Ptx, Dtx, Ttx and Hib as described previously <xref rid="bib0120" ref-type="bibr">[24]</xref>. Anti-HBsAg antibody levels were measured using an anti-HBsAg enzyme immunoassay kit (ETI-AB-AUK-3, Diasorin, Italy). Type 1 poliovirus IgG levels were determined by a neutralization assay as described previously <xref rid="bib0125" ref-type="bibr">[25]</xref>. Infants with inadequate vaccine responses were offered revaccination.</p></sec><sec id="sec0055"><label>2.9</label><title>Statistical analysis</title><p>Non-parametric tests were used to compare immune responses, hematology and biochemistry parameters. We reported local and systemic AEs occurring 8 weeks after vaccination. Infants could contribute to several AEs, and those with more than one report of the same event were assigned to the highest grade recorded for that condition if it was ongoing. If an event occurred in 2 or more distinct episodes, these were considered separate events. Two-tailed Mann&#x02013;Whitney tests were used to compare the two trial randomization arms, and Wilcoxon matched-pairs tests assessed the changes in an infant's responses over time. The alpha level was set at &#x0003c;0.05 for statistical significance. Poisson models were used to examine replicate wells of the ELISPOT assays and extreme outliers that were identified (using a Bonferroni correction for multiple testing) were excluded prior to averaging. Data analysis was conducted with Stata version 12 (StataCorp, College Station, Texas).</p></sec></sec><sec sec-type="results" id="sec0060"><label>3</label><title>Results</title><sec id="sec0065"><label>3.1</label><title>Trial participants</title><p>Between February and November 2010, 182 mothers were screened, of whom 104 were eligible for the study. Of the 102 deliveries, 94 infants were eligible for the study, including 79 breast feeders and 15 formula feeders (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>). At 20 weeks of age, 73 infants were randomized to receive the MVA.HIVA vaccine (<italic>n</italic>&#x000a0;=&#x000a0;36) or no treatment (<italic>n</italic>&#x000a0;=&#x000a0;37). Mothers of randomized infants had a median age of 27 years (IQR 22-31) and were enrolled at a median gestational age of 29 weeks (IQR 24, 32). The median infant birth weight was 3.1&#x000a0;kg (IQR 2.95, 3.4). Seventy-one infants completed visit 10 (48 weeks) within the scheduled visit window, with one infant attending late, giving an overall retention of 99% at 48 weeks. There were no significant differences between the 2 groups at baseline (<xref rid="tbl0005" ref-type="table">Table 1</xref>).</p></sec><sec id="sec0070"><label>3.2</label><title>MVA.HIVA was well tolerated</title><p>Most vaccinated infants had pain, redness and hardness on day 1 and 2 post-vaccination (<xref rid="tbl0010" ref-type="table">Table 2</xref>). One week post-vaccination, 1 infant had grade 1 pain, 2 had redness measuring 0.3 and 0.5&#x000a0;cm and 14 had hardness with median (range) diameter of 0.5 (0.1&#x02013;1)&#x000a0;cm. All these events had resolved by 8 weeks post-vaccination. Three infants had lymphadenopathy measuring 0.5&#x000a0;cm in 2 infants and 0.6&#x000a0;cm in 1 infant at week 1; these resolved by week 8. Another infant had lymphadenopathy measuring 0.5&#x000a0;cm at week 8 (<xref rid="tbl0010" ref-type="table">Table 2</xref>). As previously reported, 58% infants displayed hematologic toxicities pre-randomization <xref rid="bib0025" ref-type="bibr">[5]</xref>. However, there were no significant hematology or biochemistry differences between the vaccinees and controls post-vaccination (<xref rid="tbl0015" ref-type="table">Table 3</xref>). There were 8 severe adverse events, 5 in the vaccine arm and 3 in the control arm. Among vaccinees, 1 infant had an upper respiratory tract infection, 2 had gastroenteritis, 1 had septicemia and 1 had a depressed skull fracture, while among controls, 2 infants had neutropenia and 1 had pneumonia (<xref rid="tbl0020" ref-type="table">Table 4</xref>). None of these events were considered vaccine-related.</p></sec><sec id="sec0075"><label>3.3</label><title>Vaccination did not induce significant, detectable anti-HIV-1 T-cell responses</title><p>A total of 262 <italic>ex vivo</italic> IFN-&#x003b3; ELISPOT assays were conducted for 72 infants, with 18, 28, 14 and 12 infants tested at 5, 4, 3 and fewer time points, respectively. Results were also obtained for a total of 142 cultured assays from 51 infants with 39 and 12 infants tested at 3 and 2 time points, respectively. Overall, no positive HIV-1-specific T-cell responses were detected using either of the IFN-&#x003b3; ELISPOT assays, although transiently higher frequencies were detected in the MVA.HIVA arm (<italic>p</italic>&#x000a0;=&#x000a0;0.002) in fresh <italic>ex vivo</italic> assays, but not above the threshold frequencies considered as a positive result (Supplementary Table S1). Note, that infants have up to 15-fold higher PBMC counts per 1&#x000a0;ml of peripheral blood compared to adults.</p></sec><sec id="sec0080"><label>3.4</label><title>Except for HBV, MVA.HIVA administration did not affect KEPI induction of protective antibodies</title><p>KEPI vaccinations elicited protective antibody levels to Hib, poliovirus, diphtheria, tetanus and pertussis in a majority of the infants with no statistically significant differences between the two arms (<xref rid="tbl0025" ref-type="table">Table 5</xref>). For HBV, immune response to vaccine differed between the two groups; 71% of MVA.HIVA arm subjects versus 92% of control subjects achieved protective antibody levels to HBV (&#x02265;10&#x000a0;mIU&#x000a0;ml<sup>&#x02212;1</sup>) 1 week post-vaccination (<italic>p</italic>&#x000a0;=&#x000a0;0.05), reflecting the greater drop in levels in the MVA.HIVA arm between weeks 19 and 21 (<italic>p</italic>&#x000a0;=&#x000a0;0.025).</p></sec><sec id="sec0085"><label>3.5</label><title>MVA.HIVA recipients remained HIV-1 test negative</title><p>Infants&#x02019; blood was regularly tested for HIV-1-specific DNA or antibodies. Post-randomization, all infants remained HIV negative at repeated serial testing.</p></sec></sec><sec sec-type="discussion" id="sec0090"><label>4</label><title>Discussion</title><p>MVA is a boosting vector for recombinant subunit vaccines under development for prevention of a number of infectious diseases <xref rid="bib0070" ref-type="bibr">[14]</xref> for use in adults and infants <xref rid="bib0115 bib0130 bib0135" ref-type="bibr">[23,26,27]</xref>. The PedVacc 002 trial reported here demonstrated safety of MVA-vectored vaccines expressing an HIV-1-derived immunogen in 20-week-old HIV-1-negative African infants born to HIV-1-positive mothers.</p><p>Administration of one low MVA.HIVA vaccine dose without a heterologous prime or boost was not sufficiently immunogenic to induce HIV-1-specific, IFN-&#x003b3;-producing T cells in the circulating blood of 20-week-old infants. There was also no indication of induction or boosting of infants&#x02019; HIV-1-specific T-cell responses through exposure to their mother's virus. This is neither unexpected nor discouraging for future use of this vaccine modality. First, because of the young age of vaccine recipients, we used a low intramuscular dose of MVA.HIVA, which was 4-fold lower than the adult dose of 2&#x000a0;&#x000d7;&#x000a0;10<sup>8</sup>&#x000a0;pfu <xref rid="bib0075" ref-type="bibr">[15]</xref> likely to be used in future studies. In addition, we and others have shown that vaccines vectored by MVA are poor primers of transgene-specific T-cell responses, but when given to well-primed individuals such as HIV-1-positive patients on ART or volunteers whose responses have already been expanded by DNA- and/or simian adenovirus-vectored vaccines, rMVA delivered up to a 10-fold boost to the existing frequencies of transgene-specific T-cells <xref rid="bib0075 bib0140" ref-type="bibr">[15,28]</xref>. In our parallel PedVacc trials 001 and 002, this prudent rMVA vaccine dose was administered as the first stage of developing a recombinant BCG-MVA regimen with a possible extension to a dual HIV-TB vaccine platform <xref rid="bib0145 bib0150 bib0155 bib0160 bib0165 bib0170 bib0175" ref-type="bibr">[29&#x02013;35]</xref>. Since the conception of these trials in 2007, both the immunogen design and its presentation to the immune system have evolved. Recently, a prime with non-replicating recombinant simian adenovirus followed by an rMVA boost was shown to induce high frequencies of transgene-specific T cells in UK adults <xref rid="bib0180 bib0185 bib0190" ref-type="bibr">[36&#x02013;38]</xref>. The immunogen HIVA has been replaced by a pan-clade immunogen based on the most conserved regions of the HIV-1 proteome <xref rid="bib0180 bib0195" ref-type="bibr">[36,39]</xref>, which addresses virus diversity and escape more efficiently <xref rid="bib0140" ref-type="bibr">[28]</xref>. Furthermore, for a final vaccine regimen, an efficient T-cell vaccine will likely be combined with vaccines inducing broadly neutralizing antibodies when these become available <xref rid="bib0200" ref-type="bibr">[40]</xref>.</p><p>MVA.HIVA did not interfere with responses to polio, diphtheria, pertussis, tetanus or Hib vaccines. However, a higher proportion of vaccinated infants failed to develop protective levels of antibodies to HBV. This difference was not observed in the PedVacc 001 study, where MVA.HIVA was administered to HIV-1-negative children of HIV-1-negative Gambian mothers and similar responses to the six childhood vaccines were found in vaccinees and controls <xref rid="bib0115" ref-type="bibr">[23]</xref>. A very good safety record of MVA.HIVA also concurs with candidate TB vaccine MVA85A, which was well tolerated in clinical trials in infants <xref rid="bib0130 bib0135 bib0205 bib0210" ref-type="bibr">[26,27,41,42]</xref>. In the PACTG 326 and HPTN 027 studies, where non-replicating canarypoxviruses were administered to HIV-1-exposed uninfected (HEU) infants at birth, no differences in vaccine responses were found between infants and adults <xref rid="bib0100 bib0105 bib0110" ref-type="bibr">[20&#x02013;22]</xref>. Nevertheless, immune system deficits that impair immune responses to childhood vaccines were described among HEU infants, not only resulting from abnormalities in the immune system <xref rid="bib0215 bib0220 bib0225 bib0230" ref-type="bibr">[43&#x02013;46]</xref>, but also from antiretroviral prophylaxis administered to mothers for PMTCT <xref rid="bib0225" ref-type="bibr">[45]</xref>. Humoral vaccine responses among HEU infants were variable with similar responses being described 2 weeks after last vaccination <xref rid="bib0235" ref-type="bibr">[47]</xref> and lower HBV and tetanus titers 4 weeks after last vaccination <xref rid="bib0240" ref-type="bibr">[48]</xref> when compared to HIV-1-unexposed infants. In addition, HBV antibody level declined by up to 50% over time among HEU infants 6 months after the third vaccination dose emphasizing the need for boost vaccinations in this group <xref rid="bib0245" ref-type="bibr">[49]</xref>. Thus, reduced responses to HBV vaccine among HEU recipients of MVA.HIVA require further evaluation.</p><p>There was a high level of retention in this study despite the intensive study visits, demonstrating the feasibility of conducting vaccine studies among infants in the region. This finding is similar to other infant HIV-1 vaccine trials conducted in Africa <xref rid="bib0100 bib0105 bib0110 bib0115" ref-type="bibr">[20&#x02013;23]</xref> and provides reassurance for future vaccine evaluations in this age group.</p><p>In conclusion, MVA.HIVA was safe but not sufficiently immunogenic as a stand-alone vaccine in African infants. The safety profile demonstrated in PedVacc 001 <xref rid="bib0115" ref-type="bibr">[23]</xref> and 002 trials in infants, and immunogenicity of MVA-vectored vaccines observed in heterologous prime-boost regimens <xref rid="bib0145 bib0150 bib0155 bib0160 bib0165 bib0170 bib0175" ref-type="bibr">[29&#x02013;35]</xref> support the use of MVA as a vaccine vector in infants. In addition to evaluating vaccine performance, both trials built capacity by using local ethics and regulatory review processes and establishing/expanding local infant HIV-1 vaccine trial expertise and facilities for evaluations of future vaccine candidates.</p></sec></body><back><ref-list><title>References</title><ref id="bib0005"><label>1</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name><surname>Bae</surname><given-names>W.H.</given-names></name><name><surname>Wester</surname><given-names>C.</given-names></name><name><surname>Smeaton</surname><given-names>L.M.</given-names></name><name><surname>Shapiro</surname><given-names>R.L.</given-names></name><name><surname>Lockman</surname><given-names>S.</given-names></name><name><surname>Onyait</surname><given-names>K.</given-names></name></person-group><article-title>Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants</article-title><source>AIDS</source><volume>22</volume><year>2008</year><fpage>1633</fpage><lpage>1640</lpage><pub-id pub-id-type="pmid">18670224</pub-id></element-citation></ref><ref id="bib0010"><label>2</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name><surname>Chappuy</surname><given-names>H.</given-names></name><name><surname>Treluyer</surname><given-names>J.M.</given-names></name><name><surname>Jullien</surname><given-names>V.</given-names></name><name><surname>Dimet</surname><given-names>J.</given-names></name><name><surname>Rey</surname><given-names>E.</given-names></name><name><surname>Fouche</surname><given-names>M.</given-names></name></person-group><article-title>Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women</article-title><source>Antimicrob Agents Chemother</source><volume>48</volume><year>2004</year><fpage>4332</fpage><lpage>4336</lpage><pub-id pub-id-type="pmid">15504861</pub-id></element-citation></ref><ref id="bib0015"><label>3</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name><surname>Chappuy</surname><given-names>H.</given-names></name><name><surname>Treluyer</surname><given-names>J.M.</given-names></name><name><surname>Rey</surname><given-names>E.</given-names></name><name><surname>Dimet</surname><given-names>J.</given-names></name><name><surname>Fouche</surname><given-names>M.</given-names></name><name><surname>Firtion</surname><given-names>G.</given-names></name></person-group><article-title>Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus</article-title><source>Am J Obstet Gynecol</source><volume>191</volume><year>2004</year><fpage>558</fpage><lpage>562</lpage><pub-id pub-id-type="pmid">15343237</pub-id></element-citation></ref><ref id="bib0020"><label>4</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name><surname>Feiterna-Sperling</surname><given-names>C.</given-names></name><name><surname>Weizsaecker</surname><given-names>K.</given-names></name><name><surname>Buhrer</surname><given-names>C.</given-names></name><name><surname>Casteleyn</surname><given-names>S.</given-names></name><name><surname>Loui</surname><given-names>A.</given-names></name><name><surname>Schmitz</surname><given-names>T.</given-names></name></person-group><article-title>Hematologic effects of maternal antiretroviral therapy and transmission prophylaxis in HIV-1-exposed uninfected newborn infants</article-title><source>J Acquir Immune Defic Syndr</source><volume>45</volume><year>2007</year><fpage>43</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">17356471</pub-id></element-citation></ref><ref id="bib0025"><label>5</label><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name><surname>Njuguna</surname><given-names>I.</given-names></name><name><surname>Reilly</surname><given-names>M.</given-names></name><name><surname>Jaoko</surname><given-names>W.</given-names></name><name><surname>Gichuhi</surname><given-names>C.</given-names></name><name><surname>Ambler</surname><given-names>G.</given-names></name><name><surname>Maleche-Obimbo</surname><given-names>E.</given-names></name></person-group><article-title>Infant neutrapenia associated with breastfeeding during maternal antiretroviral treatment for prevention of mother-to-child transmission of HIV</article-title><source>Retrovirology</source><volume>6</volume><year>2014</year><fpage>1</fpage><lpage>5</lpage></element-citation></ref><ref id="bib0030"><label>6</label><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name><surname>Pacheco</surname><given-names>S.E.</given-names></name><name><surname>McIntosh</surname><given-names>K.</given-names></name><name><surname>Lu</surname><given-names>M.</given-names></name><name><surname>Mofenson</surname><given-names>L.M.</given-names></name><name><surname>Diaz</surname><given-names>C.</given-names></name><name><surname>Foca</surname><given-names>M.</given-names></name></person-group><article-title>Effect of perinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: An analysis of the women and infants transmission study</article-title><source>J Infect Dis</source><volume>194</volume><year>2006</year><fpage>1089</fpage><lpage>1097</lpage><pub-id pub-id-type="pmid">16991083</pub-id></element-citation></ref><ref id="bib0035"><label>7</label><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>R.L.</given-names></name><name><surname>Holland</surname><given-names>D.T.</given-names></name><name><surname>Capparelli</surname><given-names>E.</given-names></name><name><surname>Lockman</surname><given-names>S.</given-names></name><name><surname>Thior</surname><given-names>I.</given-names></name><name><surname>Wester</surname><given-names>C.</given-names></name></person-group><article-title>Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment</article-title><source>J Infect Dis</source><volume>192</volume><year>2005</year><fpage>720</fpage><lpage>727</lpage><pub-id pub-id-type="pmid">16088821</pub-id></element-citation></ref><ref id="bib0040"><label>8</label><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name><surname>Six Week Extended-Dose Nevirapine Study</surname></name><name><surname>Bedri</surname><given-names>T.A.</given-names></name><name><surname>Gudetta</surname><given-names>B.</given-names></name><name><surname>Isehak</surname><given-names>A.</given-names></name><name><surname>Kumbi</surname><given-names>S.</given-names></name><name><surname>Lulseged</surname><given-names>S.</given-names></name></person-group><article-title>Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials</article-title><source>Lancet</source><volume>372</volume><year>2008</year><fpage>300</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">18657709</pub-id></element-citation></ref><ref id="bib0045"><label>9</label><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>B.A.</given-names></name><name><surname>Mbori-Ngacha</surname><given-names>D.</given-names></name><name><surname>Lavreys</surname><given-names>L.</given-names></name><name><surname>John-Stewart</surname><given-names>G.C.</given-names></name><name><surname>Nduati</surname><given-names>R.</given-names></name><name><surname>Panteleeff</surname><given-names>D.D.</given-names></name></person-group><article-title>Comparison of human immunodeficiency virus type 1 viral loads in Kenyan women, men, and infants during primary and early infection</article-title><source>J Virol</source><volume>77</volume><year>2003</year><fpage>7120</fpage><lpage>7123</lpage><pub-id pub-id-type="pmid">12768032</pub-id></element-citation></ref><ref id="bib0050"><label>10</label><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name><surname>Mo</surname><given-names>H.</given-names></name><name><surname>Monard</surname><given-names>S.</given-names></name><name><surname>Pollack</surname><given-names>H.</given-names></name><name><surname>Ip</surname><given-names>J.</given-names></name><name><surname>Rochford</surname><given-names>G.</given-names></name><name><surname>Wu</surname><given-names>L.</given-names></name></person-group><article-title>Expression patterns of the HIV type 1 coreceptors CCR5 and CXCR4 on CD4+ T cells and monocytes from cord and adult blood</article-title><source>AIDS Res Hum Retroviruses</source><volume>14</volume><year>1998</year><fpage>607</fpage><lpage>617</lpage><pub-id pub-id-type="pmid">9591715</pub-id></element-citation></ref><ref id="bib0055"><label>11</label><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name><surname>Luzuriaga</surname><given-names>K.</given-names></name><name><surname>Sullivan</surname><given-names>J.L.</given-names></name></person-group><article-title>Pediatric HIV-1 infection: advances and remaining challenges</article-title><source>AIDS Rev</source><volume>4</volume><year>2002</year><fpage>21</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">11998780</pub-id></element-citation></ref><ref id="bib0060"><label>12</label><element-citation publication-type="journal" id="sbref0060"><person-group person-group-type="author"><name><surname>Farber</surname><given-names>D.L.</given-names></name><name><surname>Yudanin</surname><given-names>N.A.</given-names></name><name><surname>Restifo</surname><given-names>N.P.</given-names></name></person-group><article-title>Human memory T cells: generation, compartmentalization and homeostasis</article-title><source>Nat Rev Immunol</source><volume>14</volume><year>2014</year><fpage>24</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">24336101</pub-id></element-citation></ref><ref id="bib0065"><label>13</label><element-citation publication-type="journal" id="sbref0065"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>C.K.</given-names></name><name><surname>McFarland</surname><given-names>E.</given-names></name></person-group><article-title>Vaccines for prevention of mother-to-child transmission of HIV</article-title><source>Curr Opin HIV AIDS</source><volume>3</volume><year>2008</year><fpage>151</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">19372958</pub-id></element-citation></ref><ref id="bib0070"><label>14</label><element-citation publication-type="journal" id="sbref0070"><person-group person-group-type="author"><name><surname>Gomez</surname><given-names>C.E.</given-names></name><name><surname>Perdiguero</surname><given-names>B.</given-names></name><name><surname>Garcia-Arriaza</surname><given-names>J.</given-names></name><name><surname>Esteban</surname><given-names>M.</given-names></name></person-group><article-title>Clinical applications of attenuated MVA poxvirus strain</article-title><source>Expert Rev Vaccines</source><volume>12</volume><year>2013</year><fpage>1395</fpage><lpage>1416</lpage><pub-id pub-id-type="pmid">24168097</pub-id></element-citation></ref><ref id="bib0075"><label>15</label><element-citation publication-type="journal" id="sbref0075"><person-group person-group-type="author"><name><surname>Hanke</surname><given-names>T.</given-names></name><name><surname>Goonetilleke</surname><given-names>N.</given-names></name><name><surname>McMichael</surname><given-names>A.J.</given-names></name><name><surname>Dorrell</surname><given-names>L.</given-names></name></person-group><article-title>Clinical experience with plasmid DNA- and modified vaccinia vaccine Ankara (MVA)-vectored HIV-1 clade A vaccine inducing T cells</article-title><source>J Gen Virol</source><volume>88</volume><year>2007</year><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">17170430</pub-id></element-citation></ref><ref id="bib0080"><label>16</label><element-citation publication-type="journal" id="sbref0080"><person-group person-group-type="author"><name><surname>Hanke</surname><given-names>T.</given-names></name><name><surname>McMichael</surname><given-names>A.J.</given-names></name></person-group><article-title>Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya</article-title><source>Nat Med</source><volume>6</volume><year>2000</year><fpage>951</fpage><lpage>955</lpage><pub-id pub-id-type="pmid">10973301</pub-id></element-citation></ref><ref id="bib0085"><label>17</label><element-citation publication-type="journal" id="sbref0085"><person-group person-group-type="author"><name><surname>Borkowsky</surname><given-names>W.</given-names></name><name><surname>Wara</surname><given-names>D.</given-names></name><name><surname>Fenton</surname><given-names>T.</given-names></name><name><surname>McNamara</surname><given-names>J.</given-names></name><name><surname>Kang</surname><given-names>M.</given-names></name><name><surname>Mofenson</surname><given-names>L.</given-names></name></person-group><article-title>Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators</article-title><source>J Infect Dis</source><volume>181</volume><year>2000</year><fpage>890</fpage><lpage>896</lpage><pub-id pub-id-type="pmid">10720509</pub-id></element-citation></ref><ref id="bib0090"><label>18</label><element-citation publication-type="journal" id="sbref0090"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>C.K.</given-names></name><name><surname>Wara</surname><given-names>D.W.</given-names></name><name><surname>Kang</surname><given-names>M.</given-names></name><name><surname>Fenton</surname><given-names>T.</given-names></name><name><surname>Hawkins</surname><given-names>E.</given-names></name><name><surname>McNamara</surname><given-names>J.</given-names></name></person-group><article-title>Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women</article-title><source>Clin Infect Dis</source><volume>32</volume><year>2001</year><fpage>801</fpage><lpage>807</lpage><pub-id pub-id-type="pmid">11229849</pub-id></element-citation></ref><ref id="bib0095"><label>19</label><element-citation publication-type="journal" id="sbref0095"><person-group person-group-type="author"><name><surname>McFarland</surname><given-names>E.J.</given-names></name><name><surname>Borkowsky</surname><given-names>W.</given-names></name><name><surname>Fenton</surname><given-names>T.</given-names></name><name><surname>Wara</surname><given-names>D.</given-names></name><name><surname>McNamara</surname><given-names>J.</given-names></name><name><surname>Samson</surname><given-names>P.</given-names></name></person-group><article-title>Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine</article-title><source>J Infect Dis</source><volume>184</volume><year>2001</year><fpage>1331</fpage><lpage>1335</lpage><pub-id pub-id-type="pmid">11679925</pub-id></element-citation></ref><ref id="bib0100"><label>20</label><element-citation publication-type="journal" id="sbref0100"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>D.C.</given-names></name><name><surname>McFarland</surname><given-names>E.J.</given-names></name><name><surname>Muresan</surname><given-names>P.</given-names></name><name><surname>Fenton</surname><given-names>T.</given-names></name><name><surname>McNamara</surname><given-names>J.</given-names></name><name><surname>Read</surname><given-names>J.S.</given-names></name></person-group><article-title>Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women</article-title><source>J Infect Dis</source><volume>192</volume><year>2005</year><fpage>2129</fpage><lpage>2133</lpage><pub-id pub-id-type="pmid">16288378</pub-id></element-citation></ref><ref id="bib0105"><label>21</label><element-citation publication-type="journal" id="sbref0105"><person-group person-group-type="author"><name><surname>McFarland</surname><given-names>E.J.</given-names></name><name><surname>Johnson</surname><given-names>D.C.</given-names></name><name><surname>Muresan</surname><given-names>P.</given-names></name><name><surname>Fenton</surname><given-names>T.</given-names></name><name><surname>Tomaras</surname><given-names>G.D.</given-names></name><name><surname>McNamara</surname><given-names>J.</given-names></name></person-group><article-title>HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers</article-title><source>AIDS</source><volume>20</volume><year>2006</year><fpage>1481</fpage><lpage>1489</lpage><pub-id pub-id-type="pmid">16847402</pub-id></element-citation></ref><ref id="bib0110"><label>22</label><element-citation publication-type="journal" id="sbref0110"><person-group person-group-type="author"><name><surname>Kintu</surname><given-names>K.</given-names></name><name><surname>Andrew</surname><given-names>P.</given-names></name><name><surname>Musoke</surname><given-names>P.</given-names></name><name><surname>Richardson</surname><given-names>P.</given-names></name><name><surname>Asiimwe-Kateera</surname><given-names>B.</given-names></name><name><surname>Nakyanzi</surname><given-names>T.</given-names></name></person-group><article-title>Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in Uganda: results from the first HIV vaccine trial in infants in Africa</article-title><source>J Acquir Immune Defic Syndr</source><volume>63</volume><year>2013</year><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">23221981</pub-id></element-citation></ref><ref id="bib0115"><label>23</label><element-citation publication-type="journal" id="sbref0115"><person-group person-group-type="author"><name><surname>Afolabi</surname><given-names>M.O.</given-names></name><name><surname>Ndure</surname><given-names>J.</given-names></name><name><surname>Drammeh</surname><given-names>A.</given-names></name><name><surname>Darboe</surname><given-names>F.</given-names></name><name><surname>Mehedi</surname><given-names>S.-R.</given-names></name><name><surname>Rowland-Jones</surname><given-names>S.L.</given-names></name></person-group><article-title>A phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infants</article-title><source>PLoS One</source><volume>8</volume><year>2013</year><fpage>e78289</fpage><pub-id pub-id-type="pmid">24205185</pub-id></element-citation></ref><ref id="bib0120"><label>24</label><element-citation publication-type="journal" id="sbref0120"><person-group person-group-type="author"><name><surname>van Gageldonk</surname><given-names>P.G.</given-names></name><name><surname>van Schaijk</surname><given-names>F.G.</given-names></name><name><surname>van der Klis</surname><given-names>F.R.</given-names></name><name><surname>Berbers</surname><given-names>G.A.</given-names></name></person-group><article-title>Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus</article-title><source>J Immunol Methods</source><volume>335</volume><year>2008</year><fpage>79</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">18407287</pub-id></element-citation></ref><ref id="bib0125"><label>25</label><element-citation publication-type="journal" id="sbref0125"><person-group person-group-type="author"><name><surname>Eggers</surname><given-names>M.</given-names></name><name><surname>Terletskaia-Ladwig</surname><given-names>E.</given-names></name><name><surname>Rabenau</surname><given-names>H.F.</given-names></name><name><surname>Doerr</surname><given-names>H.W.</given-names></name><name><surname>Diedrich</surname><given-names>S.</given-names></name><name><surname>Enders</surname><given-names>G.</given-names></name></person-group><article-title>Immunity status of adults and children against poliomyelitis virus type 1 strains CHAT and Sabin (LSc-2ab) in Germany</article-title><source>BMC Infect Dis</source><volume>10</volume><year>2010</year><fpage>347</fpage><pub-id pub-id-type="pmid">21143885</pub-id></element-citation></ref><ref id="bib0130"><label>26</label><element-citation publication-type="journal" id="sbref0130"><person-group person-group-type="author"><name><surname>Ota</surname><given-names>M.O.</given-names></name><name><surname>Odutola</surname><given-names>A.A.</given-names></name><name><surname>Owiafe</surname><given-names>P.K.</given-names></name><name><surname>Donkor</surname><given-names>S.</given-names></name><name><surname>Owolabi</surname><given-names>O.A.</given-names></name><name><surname>Brittain</surname><given-names>N.J.</given-names></name></person-group><article-title>Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants</article-title><source>Sci Transl Med</source><volume>3</volume><year>2011</year><fpage>88ra56</fpage></element-citation></ref><ref id="bib0135"><label>27</label><element-citation publication-type="journal" id="sbref0135"><person-group person-group-type="author"><name><surname>Scriba</surname><given-names>T.J.</given-names></name><name><surname>Tameris</surname><given-names>M.</given-names></name><name><surname>Mansoor</surname><given-names>N.</given-names></name><name><surname>Smit</surname><given-names>E.</given-names></name><name><surname>van der Merwe</surname><given-names>L.</given-names></name><name><surname>Mauff</surname><given-names>K.</given-names></name></person-group><article-title>Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants</article-title><source>J Infect Dis</source><volume>203</volume><year>2011</year><fpage>1832</fpage><lpage>1843</lpage><pub-id pub-id-type="pmid">21606542</pub-id></element-citation></ref><ref id="bib0140"><label>28</label><element-citation publication-type="journal" id="sbref0140"><person-group person-group-type="author"><name><surname>Hanke</surname><given-names>T.</given-names></name></person-group><article-title>Conserved immunogens in prime-bost strategies for te next-generation HIV-1 vaccines</article-title><source>Expert Opin Biol Ther</source><volume>14</volume><year>2014</year><fpage>601</fpage><lpage>616</lpage><pub-id pub-id-type="pmid">24490585</pub-id></element-citation></ref><ref id="bib0145"><label>29</label><element-citation publication-type="journal" id="sbref0145"><person-group person-group-type="author"><name><surname>Hopkins</surname><given-names>R.</given-names></name><name><surname>Bridgeman</surname><given-names>A.</given-names></name><name><surname>Bourne</surname><given-names>C.</given-names></name><name><surname>Mbewe-Mwula</surname><given-names>A.</given-names></name><name><surname>Sadoff</surname><given-names>J.C.</given-names></name><name><surname>Both</surname><given-names>G.W.</given-names></name></person-group><article-title>Optimizing HIV-1-specific CD8<sup>+</sup> T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors</article-title><source>Eur J Immunol</source><volume>41</volume><year>2011</year><fpage>3542</fpage><lpage>3552</lpage><pub-id pub-id-type="pmid">21932450</pub-id></element-citation></ref><ref id="bib0150"><label>30</label><element-citation publication-type="journal" id="sbref0150"><person-group person-group-type="author"><name><surname>Hopkins</surname><given-names>R.</given-names></name><name><surname>Bridgeman</surname><given-names>A.</given-names></name><name><surname>Joseph</surname><given-names>J.</given-names></name><name><surname>Gilbert</surname><given-names>S.C.</given-names></name><name><surname>McShane</surname><given-names>H.</given-names></name><name><surname>Hanke</surname><given-names>T.</given-names></name></person-group><article-title>Dual neonate vaccine platform against HIV-1 and M. tuberculosis</article-title><source>PLoS One</source><volume>6</volume><year>2011</year><fpage>e20067</fpage><pub-id pub-id-type="pmid">21603645</pub-id></element-citation></ref><ref id="bib0155"><label>31</label><element-citation publication-type="journal" id="sbref0155"><person-group person-group-type="author"><name><surname>Im</surname><given-names>E.J.</given-names></name><name><surname>Saubi</surname><given-names>N.</given-names></name><name><surname>Virgili</surname><given-names>G.</given-names></name><name><surname>Sander</surname><given-names>C.</given-names></name><name><surname>Teoh</surname><given-names>D.</given-names></name><name><surname>Gatell</surname><given-names>J.M.</given-names></name></person-group><article-title>Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding</article-title><source>J Virol</source><volume>81</volume><year>2007</year><fpage>9408</fpage><lpage>9418</lpage><pub-id pub-id-type="pmid">17596303</pub-id></element-citation></ref><ref id="bib0160"><label>32</label><element-citation publication-type="journal" id="sbref0160"><person-group person-group-type="author"><name><surname>Rosario</surname><given-names>M.</given-names></name><name><surname>Fulkerson</surname><given-names>J.</given-names></name><name><surname>Soneji</surname><given-names>S.</given-names></name><name><surname>Parker</surname><given-names>J.</given-names></name><name><surname>Im</surname><given-names>E.J.</given-names></name><name><surname>Borthwick</surname><given-names>N.</given-names></name></person-group><article-title>Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques</article-title><source>J Virol</source><volume>84</volume><year>2010</year><fpage>7815</fpage><lpage>7821</lpage><pub-id pub-id-type="pmid">20484495</pub-id></element-citation></ref><ref id="bib0165"><label>33</label><element-citation publication-type="journal" id="sbref0165"><person-group person-group-type="author"><name><surname>Rosario</surname><given-names>M.</given-names></name><name><surname>Hopkins</surname><given-names>R.</given-names></name><name><surname>Fulkerson</surname><given-names>J.</given-names></name><name><surname>Borthwick</surname><given-names>N.</given-names></name><name><surname>Quigley</surname><given-names>M.F.</given-names></name><name><surname>Joseph</surname><given-names>J.</given-names></name></person-group><article-title>Novel recombinant <italic>Mycobacterium bovis</italic> BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques</article-title><source>J Virol</source><volume>84</volume><year>2010</year><fpage>5898</fpage><lpage>5908</lpage><pub-id pub-id-type="pmid">20375158</pub-id></element-citation></ref><ref id="bib0170"><label>34</label><element-citation publication-type="journal" id="sbref0170"><person-group person-group-type="author"><name><surname>Saubi</surname><given-names>N.</given-names></name><name><surname>Gea-Mallorqui</surname><given-names>E.</given-names></name><name><surname>Ferrer</surname><given-names>P.</given-names></name><name><surname>Hurtado</surname><given-names>C.</given-names></name><name><surname>Sanchez-Ubeda</surname><given-names>S.</given-names></name><name><surname>Eto</surname><given-names>Y.</given-names></name></person-group><article-title>Engineering new mycobacterial vaccine design for HIV&#x02013;TB pediatric vaccine vectored by lysine auxotroph of BCG</article-title><source>Mol Ther Methods Clin Dev</source><volume>1</volume><year>2014</year><fpage>14017</fpage></element-citation></ref><ref id="bib0175"><label>35</label><element-citation publication-type="journal" id="sbref0175"><person-group person-group-type="author"><name><surname>Saubi</surname><given-names>N.</given-names></name><name><surname>Im</surname><given-names>E.J.</given-names></name><name><surname>Fernandez-Lloris</surname><given-names>R.</given-names></name><name><surname>Gil</surname><given-names>O.</given-names></name><name><surname>Cardona</surname><given-names>P.J.</given-names></name><name><surname>Gatell</surname><given-names>J.M.</given-names></name></person-group><article-title>Newborn mice vaccination with BCG.HIVA&#x000a0;+&#x000a0;MVA.HIVA enhances HIV-1-specific immune responses: influence of age and immunization routes</article-title><source>Clin Dev Immunol</source><volume>2011</volume><year>2011</year><fpage>516219</fpage><pub-id pub-id-type="pmid">21603216</pub-id></element-citation></ref><ref id="bib0180"><label>36</label><element-citation publication-type="journal" id="sbref0180"><person-group person-group-type="author"><name><surname>Borthwick</surname><given-names>N.</given-names></name><name><surname>Ahmed</surname><given-names>T.</given-names></name><name><surname>Ondondo</surname><given-names>B.</given-names></name><name><surname>Hayes</surname><given-names>P.</given-names></name><name><surname>Rose</surname><given-names>A.</given-names></name><name><surname>Ebrahimsa</surname><given-names>U.</given-names></name></person-group><article-title>Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1</article-title><source>Mol Ther</source><volume>22</volume><year>2014</year><fpage>464</fpage><lpage>475</lpage><pub-id pub-id-type="pmid">24166483</pub-id></element-citation></ref><ref id="bib0185"><label>37</label><element-citation publication-type="journal" id="sbref0185"><person-group person-group-type="author"><name><surname>Ewer</surname><given-names>K.J.</given-names></name><name><surname>O&#x02018;Hara</surname><given-names>G.A.</given-names></name><name><surname>Duncan</surname><given-names>C.J.</given-names></name><name><surname>Collins</surname><given-names>K.A.</given-names></name><name><surname>Sheehy</surname><given-names>S.H.</given-names></name><name><surname>Reyes-Sandoval</surname><given-names>A.</given-names></name></person-group><article-title>Protective CD8(+) T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation</article-title><source>Nat Commun</source><volume>4</volume><year>2013</year><fpage>2836</fpage><pub-id pub-id-type="pmid">24284865</pub-id></element-citation></ref><ref id="bib0190"><label>38</label><element-citation publication-type="journal" id="sbref0190"><person-group person-group-type="author"><name><surname>Sheehy</surname><given-names>S.H.</given-names></name><name><surname>Duncan</surname><given-names>C.J.</given-names></name><name><surname>Elias</surname><given-names>S.C.</given-names></name><name><surname>Choudhary</surname><given-names>P.</given-names></name><name><surname>Biswas</surname><given-names>S.</given-names></name><name><surname>Halstead</surname><given-names>F.D.</given-names></name></person-group><article-title>ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans</article-title><source>Mol Ther</source><volume>20</volume><year>2013</year><fpage>2355</fpage><lpage>2368</lpage><pub-id pub-id-type="pmid">23089736</pub-id></element-citation></ref><ref id="bib0195"><label>39</label><element-citation publication-type="journal" id="sbref0195"><person-group person-group-type="author"><name><surname>Letourneau</surname><given-names>S.</given-names></name><name><surname>Im</surname><given-names>E.-J.</given-names></name><name><surname>Mashishi</surname><given-names>T.</given-names></name><name><surname>Brereton</surname><given-names>C.</given-names></name><name><surname>Bridgeman</surname><given-names>A.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name></person-group><article-title>Design and pre-clinical evaluation of a universal HIV-1 vaccine</article-title><source>PLoS One</source><volume>2</volume><year>2007</year><fpage>e984</fpage><pub-id pub-id-type="pmid">17912361</pub-id></element-citation></ref><ref id="bib0200"><label>40</label><element-citation publication-type="journal" id="sbref0200"><person-group person-group-type="author"><name><surname>McMichael</surname><given-names>A.J.</given-names></name><name><surname>Haynes</surname><given-names>B.F.</given-names></name></person-group><article-title>Lessons learned from HIV-1 vaccine trials: new priorities and directions</article-title><source>Nat Immunol</source><volume>13</volume><year>2012</year><fpage>423</fpage><lpage>427</lpage><pub-id pub-id-type="pmid">22513323</pub-id></element-citation></ref><ref id="bib0205"><label>41</label><element-citation publication-type="journal" id="sbref0205"><person-group person-group-type="author"><name><surname>McShane</surname><given-names>H.</given-names></name><name><surname>Pathan</surname><given-names>A.A.</given-names></name><name><surname>Sander</surname><given-names>C.R.</given-names></name><name><surname>Keating</surname><given-names>S.M.</given-names></name><name><surname>Gilbert</surname><given-names>S.C.</given-names></name><name><surname>Huygen</surname><given-names>K.</given-names></name></person-group><article-title>Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans</article-title><source>Nat Med</source><volume>10</volume><year>2004</year><fpage>1240</fpage><lpage>1244</lpage><pub-id pub-id-type="pmid">15502839</pub-id></element-citation></ref><ref id="bib0210"><label>42</label><element-citation publication-type="journal" id="sbref0210"><person-group person-group-type="author"><name><surname>Tameris</surname><given-names>M.D.</given-names></name><name><surname>Hatherill</surname><given-names>M.</given-names></name><name><surname>Landry</surname><given-names>B.S.</given-names></name><name><surname>Scriba</surname><given-names>T.J.</given-names></name><name><surname>Snowden</surname><given-names>M.A.</given-names></name><name><surname>Lockhart</surname><given-names>S.</given-names></name></person-group><article-title>Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial</article-title><source>Lancet</source><volume>381</volume><year>2013</year><fpage>1021</fpage><lpage>1028</lpage><pub-id pub-id-type="pmid">23391465</pub-id></element-citation></ref><ref id="bib0215"><label>43</label><element-citation publication-type="journal" id="sbref0215"><person-group person-group-type="author"><name><surname>Clerici</surname><given-names>M.</given-names></name><name><surname>Saresella</surname><given-names>M.</given-names></name><name><surname>Colombo</surname><given-names>F.</given-names></name><name><surname>Fossati</surname><given-names>S.</given-names></name><name><surname>Sala</surname><given-names>N.</given-names></name><name><surname>Bricalli</surname><given-names>D.</given-names></name></person-group><article-title>T-lymphocyte maturation abnormalities in uninfected newborns and children with vertical exposure to HIV</article-title><source>Blood</source><volume>96</volume><year>2000</year><fpage>3866</fpage><lpage>3871</lpage><pub-id pub-id-type="pmid">11090071</pub-id></element-citation></ref><ref id="bib0220"><label>44</label><element-citation publication-type="journal" id="sbref0220"><person-group person-group-type="author"><name><surname>Kidzeru</surname><given-names>E.B.</given-names></name><name><surname>Hesseling</surname><given-names>A.C.</given-names></name><name><surname>Passmore</surname><given-names>J.A.</given-names></name><name><surname>Myer</surname><given-names>L.</given-names></name><name><surname>Gamieldien</surname><given-names>H.</given-names></name><name><surname>Tchakoute</surname><given-names>C.T.</given-names></name></person-group><article-title>In-utero exposure to maternal HIV infection alters T-cell immune responses to vaccination in HIV-uninfected infants</article-title><source>AIDS</source><year>2014</year></element-citation></ref><ref id="bib0225"><label>45</label><element-citation publication-type="journal" id="sbref0225"><person-group person-group-type="author"><name><surname>Miyamoto</surname><given-names>M.</given-names></name><name><surname>Pessoa</surname><given-names>S.D.</given-names></name><name><surname>Ono</surname><given-names>E.</given-names></name><name><surname>Machado</surname><given-names>D.M.</given-names></name><name><surname>Salomao</surname><given-names>R.</given-names></name><name><surname>Succi</surname><given-names>R.C.</given-names></name></person-group><article-title>Low CD4<sup>+</sup> T-cell levels and B-cell apoptosis in vertically HIV-exposed noninfected children and adolescents</article-title><source>J Trop Pediatr</source><volume>56</volume><year>2010</year><fpage>427</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">20388660</pub-id></element-citation></ref><ref id="bib0230"><label>46</label><element-citation publication-type="journal" id="sbref0230"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>S.D.</given-names></name><name><surname>Jeppesen</surname><given-names>D.L.</given-names></name><name><surname>Kolte</surname><given-names>L.</given-names></name><name><surname>Clark</surname><given-names>D.R.</given-names></name><name><surname>Sorensen</surname><given-names>T.U.</given-names></name><name><surname>Dreves</surname><given-names>A.M.</given-names></name></person-group><article-title>Impaired progenitor cell function in HIV-negative infants of HIV-positive mothers results in decreased thymic output and low CD4 counts</article-title><source>Blood</source><volume>98</volume><year>2001</year><fpage>398</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">11435309</pub-id></element-citation></ref><ref id="bib0235"><label>47</label><element-citation publication-type="journal" id="sbref0235"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>S.A.</given-names></name><name><surname>Groome</surname><given-names>M.</given-names></name><name><surname>Koen</surname><given-names>A.</given-names></name><name><surname>Van Niekerk</surname><given-names>N.</given-names></name><name><surname>Sewraj</surname><given-names>P.</given-names></name><name><surname>Kuwanda</surname><given-names>L.</given-names></name></person-group><article-title>Immunogenicity of seven-valent pneumococcal conjugate vaccine administered at 6, 14 and 40 weeks of age in South African infants</article-title><source>PLoS One</source><volume>8</volume><year>2013</year><fpage>e72794</fpage><pub-id pub-id-type="pmid">24015277</pub-id></element-citation></ref><ref id="bib0240"><label>48</label><element-citation publication-type="journal" id="sbref0240"><person-group person-group-type="author"><name><surname>Abramczuk</surname><given-names>B.M.</given-names></name><name><surname>Mazzola</surname><given-names>T.N.</given-names></name><name><surname>Moreno</surname><given-names>Y.M.</given-names></name><name><surname>Zorzeto</surname><given-names>T.Q.</given-names></name><name><surname>Quintilio</surname><given-names>W.</given-names></name><name><surname>Wolf</surname><given-names>P.S.</given-names></name></person-group><article-title>Impaired humoral response to vaccines among HIV-exposed uninfected infants</article-title><source>Clin Vaccine Immunol</source><volume>18</volume><year>2011</year><fpage>1406</fpage><lpage>1409</lpage><pub-id pub-id-type="pmid">21775515</pub-id></element-citation></ref><ref id="bib0245"><label>49</label><element-citation publication-type="journal" id="sbref0245"><person-group person-group-type="author"><name><surname>Thaithumyanon</surname><given-names>P.</given-names></name><name><surname>Punnahitananda</surname><given-names>S.</given-names></name><name><surname>Praisuwanna</surname><given-names>P.</given-names></name><name><surname>Thisyakorn</surname><given-names>U.</given-names></name><name><surname>Ruxrungtham</surname><given-names>K.</given-names></name></person-group><article-title>Antibody response to hepatitis B immunization in infants born to HIV-infected mothers</article-title><source>J Med Assoc Thai</source><volume>85</volume><year>2002</year><fpage>277</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">12117014</pub-id></element-citation></ref></ref-list><sec id="sec0100" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p>The following are the supplementary data to this article:<supplementary-material content-type="local-data" id="upi0005"><media xlink:href="mmc1.pdf"/></supplementary-material><supplementary-material content-type="local-data" id="upi0010"><media xlink:href="mmc2.pdf"/></supplementary-material><supplementary-material content-type="local-data" id="upi0015"><media xlink:href="mmc3.pdf"/></supplementary-material></p></sec><ack id="ack0005"><title>Acknowledgements</title><p>The authors thank the members of the DMEC Frances Gotch (Co-Chair), Glenda Gray (Co-Chair), Maria Grazia Valsecchi, Laura Guay, Aggrey Wasunna and Eduard Sanders for their guidance and input. We also acknowledge the PedVacc 002 study team and the assistance of the staff in the MRC clinical laboratories. The HIV-1 PTE Peptides were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH. Finally, we thank all study participants and their parents.</p><p>The work was supported by <funding-source id="gs0005">European and Developing Countries Clinical Trials Partnership</funding-source> (EDCTP; CT.2006.33111.002) with co-funding from <funding-source id="gs0010">Bill and Melinda Gates Foundation</funding-source>, <funding-source id="gs0015">Medical Research Council</funding-source> UK and Swedish International Development Cooperation Agency (SIDA). Research reported in this publication was also supported in part by <funding-source id="gs0020">NIAID</funding-source>, <funding-source id="gs0025">NCI</funding-source>, <funding-source id="gs0030">NIMH</funding-source>, <funding-source id="gs0035">NIDA</funding-source>, <funding-source id="gs0040">NICHD</funding-source>, <funding-source id="gs9">NHLBI</funding-source>, <funding-source id="gs0045">NIA</funding-source> of the <funding-source id="gs0050">National Institutes of Health</funding-source> under award number P30A1027757.</p><p>Clinical Trials.gov Registry (<ext-link ext-link-type="uri" xlink:href="ctgov:NCT00981695" id="intr0020">NCT00981695</ext-link>) <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/ct2/show/NCT00981695%3Fterm=MVA.HIVA+and+pedvacc%26rank=1" id="intr0025">http://www.clinicaltrials.gov/ct2/show/NCT00981695?term=MVA.HIVA+and+pedvacc&#x00026;rank=1</ext-link></p><p>The Pan African Clinical Trials Registry (PACTR2009010001152787) http://www.pactr.org/ATMWeb/appmanager/atm/atmregistry?_nfpb=true&#x00026;_windowLabel=basicSearch_1_2&#x00026;basicSearch_1_2_actionOverride=%2Fpageflows%2Ftrial%2FbasicSearch%2FviewTrail&#x00026;basicSearch_1_2id=115.</p></ack></back><floats-group><fig id="fig0005"><label>Fig. 1</label><caption><p>Trial profile. Diagram indicating the numbers of infants screened and followed up throughout the study.</p></caption><graphic xlink:href="gr1"/></fig><table-wrap id="tbl0005" position="float"><label>Table 1</label><caption><p>Characteristics of study participants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="left">Control group (<italic>n</italic>&#x000a0;=&#x000a0;37)</th><th align="left">Vaccine group (<italic>n</italic>&#x000a0;=&#x000a0;36)</th></tr></thead><tbody><tr><td align="left">Maternal characteristics at enrollment during pregnancy</td><td/><td/></tr><tr><td align="left">&#x000a0;Maternal age (years)</td><td align="char">27 (23, 31)</td><td align="char">27 (22, 30.5)</td></tr><tr><td align="left">&#x000a0;Maternal CD4<sup>+</sup> cell count (&#x003bc;l<sup>&#x02212;1</sup>)</td><td align="char">526 (428, 663)</td><td align="char">549 (443, 658.5)</td></tr><tr><td align="left">&#x000a0;Gestational age (weeks)</td><td align="char">28 (20,30)</td><td align="char">30 (27,32)</td></tr><tr><td align="left">&#x000a0;Previously used ART</td><td align="char">25 (67.6%)</td><td align="char">23 (63.8%)</td></tr><tr><td align="left">&#x000a0;On AZT-based ART</td><td align="char">16 (43.2%)</td><td align="char">17 (47.2%)</td></tr><tr><td align="left">Infant characteristics at 1 week before randomization (20 weeks postpartum)</td><td/><td/></tr><tr><td align="left">&#x000a0;Male sex</td><td align="char">16 (43.2%)</td><td align="char">16 (44.4%)</td></tr><tr><td align="left">&#x000a0;Birth weight (g)</td><td align="char">3,150 (3,000, 3,400)</td><td align="char">3,125 (2,900, 3,405)</td></tr><tr><td align="left">&#x000a0;WAZ<xref rid="tblfn0005" ref-type="table-fn">a</xref></td><td align="char">&#x02212;0.66 (&#x02212;1.22, 0.52)</td><td align="char">&#x02212;0.22 (&#x02212;0.92, 0.71)</td></tr><tr><td align="left">&#x000a0;MUAC<xref rid="tblfn0010" ref-type="table-fn">b</xref> (cm)</td><td align="char">14 (14, 15)</td><td align="char">14.5 (14, 15)</td></tr><tr><td align="left">&#x000a0;Hemoglobin (gdl<sup>&#x02212;1</sup>)</td><td align="char">11.4 (10.9, 12.3)</td><td align="char">11.85 (11.05, 12.3)</td></tr><tr><td align="left">&#x000a0;White Blood Cell count&#x000a0;&#x000d7;&#x000a0;10<sup><sup>3</sup></sup> (&#x003bc;l<sup>&#x02212;1</sup>)</td><td align="char">8.5 (7.6, 10.1)</td><td align="char">9.85 (7.70,11.35)</td></tr><tr><td align="left">&#x000a0;Platelet count&#x000a0;&#x000d7;&#x000a0;10<sup><sup>3</sup></sup> (&#x003bc;l<sup>&#x02212;1</sup>)</td><td align="char">423 (308, 531)</td><td align="char">428 (377.0, 514.5)</td></tr><tr><td align="left">&#x000a0;Neutrophil count&#x000a0;&#x000d7;&#x000a0;10<sup><sup>3</sup></sup> (&#x003bc;l<sup>&#x02212;1</sup>)</td><td align="char">1.35 (1.09, 1.59)</td><td align="char">1.45 (1.12, 2.31)</td></tr><tr><td align="left">&#x000a0;Creatinine (&#x003bc;M)</td><td align="char">37 (31, 43)</td><td align="char">36.5 (31.5, 41)</td></tr><tr><td align="left">&#x000a0;Alanine transaminase (U&#x000a0;l<sup>&#x02212;1</sup>)</td><td align="char">16 (12, 23)</td><td align="char">19.5 (14.0, 25)</td></tr></tbody></table><table-wrap-foot><fn><p>Values are given as median with interquartile range (IQR) in parentheses or <italic>n</italic> (%).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn0005"><label>a</label><p>Weight-for-age <italic>Z</italic>-score.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn0010"><label>b</label><p>Mid-upper arm circumference.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl0010" position="float"><label>Table 2</label><caption><p>Local reactogenicity during the first 8 weeks after vaccination.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><italic>n</italic>&#x000a0;=&#x000a0;36</th><th align="left">Day of vaccination</th><th align="left">Day 1</th><th align="left">Day 2</th><th align="left">Week 1</th><th align="left">Week 8</th></tr></thead><tbody><tr><td align="left">Pain</td><td align="left">1</td><td align="left">28</td><td align="left">20</td><td align="left">1</td><td align="left">0</td></tr><tr><td align="left">&#x000a0;Grade 1</td><td align="left">1</td><td align="left">28</td><td align="left">19</td><td align="left">1</td><td align="left">0</td></tr><tr><td align="left">&#x000a0;Grade 2</td><td align="left">0</td><td align="left">0</td><td align="left">1</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left">&#x000a0;Grade 3</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left">Redness</td><td align="left">0</td><td align="left">31</td><td align="left">26</td><td align="left">2<xref rid="tblfn0015" ref-type="table-fn">a</xref></td><td align="left">0</td></tr><tr><td align="left">&#x000a0;Median (range) (cm)</td><td/><td align="left">0.2 (0.1&#x02013;1)</td><td align="left">0.3 (0.1&#x02013;1.2)</td><td/><td/></tr><tr><td align="left">Hardness</td><td align="left">0</td><td align="left">17</td><td align="left">20</td><td align="left">14</td><td align="left">0</td></tr><tr><td align="left">&#x000a0;Median (range) (cm)</td><td/><td align="left">0.4 (0.1&#x02013;0.8)</td><td align="left">0.4 (0.1&#x02013;1)</td><td align="left">0.5 (0.1&#x02013;1)</td><td/></tr><tr><td align="left">Ulceration</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left">Lymph node<xref rid="tblfn0020" ref-type="table-fn">b</xref></td><td align="left">0</td><td align="left">1</td><td align="left">0</td><td align="left">3</td><td align="left">1</td></tr></tbody></table><table-wrap-foot><fn id="tblfn0015"><label>a</label><p>Two infants had redness at week 1 measuring 0.5 and 0.3&#x000a0;cm.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn0020"><label>b</label><p>One infant had lymphadenopathy noted at day 1 and week 1 at 0.6&#x000a0;cm. Two other infants had lymphadenopathy at week 1 measuring 0.5&#x000a0;cm. Another infant had lymphadenopathy measuring 0.5&#x000a0;cm at week 8. All events resolved spontaneously.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl0015" position="float"><label>Table 3</label><caption><p>Hematology and biochemistry data.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left"/><th colspan="2" align="left">Week 19<hr/></th><th colspan="2" align="left">Week 21<hr/></th><th colspan="2" align="left">Week 28<hr/></th></tr><tr><th align="left">Vaccine</th><th align="left">Control</th><th align="left">Vaccine</th><th align="left">Control</th><th align="left">Vaccine</th><th align="left">Control</th></tr></thead><tbody><tr><td align="left">Hemoglobin (g&#x000a0;dl<sup>&#x02212;1</sup>)</td><td align="char">11.4 (10.4, 12.1)</td><td align="char">11.2 (10.4, 12.3)</td><td align="char">11.3 (10.8, 11.8)</td><td align="char">11.1 (10.6, 12.4)</td><td align="char">11.0 (10.3,11.7)</td><td align="char">11.1 (10.7, 11.9)</td></tr><tr><td align="left">White cell count&#x000a0;&#x000d7;&#x000a0;10<sup>3</sup> (&#x003bc;l<sup>&#x02212;1</sup>)</td><td align="char">9.5 (6.1, 11.0)</td><td align="char">8.5 (6.3, 10.1)</td><td align="char">10.4<xref rid="tblfn0025" ref-type="table-fn">a</xref> (7.5, 12.3)</td><td align="char">8.7 (7.0, 11.3)</td><td align="char">10.3<xref rid="tblfn0030" ref-type="table-fn">b</xref> (8.1, 12.6)</td><td align="char">9.5 (7.8, 11.6)</td></tr><tr><td align="left">Platelet count &#x000a0;&#x000d7;&#x000a0;10<sup>3</sup> (&#x003bc;l<sup>&#x02212;1</sup>)</td><td align="char">412 (290.5, 517.8)</td><td align="char">319 (203.5, 524.5)</td><td align="char">426 (289, 578.3)</td><td align="char">471 (246, 576.5)</td><td align="char">407 (290, 538)</td><td align="char">464 (357, 556.5)</td></tr><tr><td align="left">Neutrophil count&#x000a0;&#x000d7;&#x000a0;10<sup>3</sup> (&#x003bc;l<sup>&#x02212;1</sup>)</td><td align="char">1.3 (1.0, 2.2)</td><td align="char">1.3 (1.0, 1.6)</td><td align="char">1.7 (1.0, 2.3)</td><td align="char">1.4 (1.0, 1.9)</td><td align="char">1.5 (1.2, 2.4)</td><td align="char">1.8<xref rid="tblfn0035" ref-type="table-fn">c</xref> (1.6, 2.9)</td></tr><tr><td align="left">Creatinine (&#x003bc;M)</td><td align="char">36.5 (31.3, 41.5)</td><td align="char">37 (31, 43.5)</td><td align="char">38.5 (33.2, 43)</td><td align="char">39 (35, 42)</td><td align="char">36 (33, 41)</td><td align="char">37.5 (31.3, 42.5)</td></tr><tr><td align="left">Alanine transaminase (U&#x000a0;l<sup>&#x02212;1</sup>)</td><td align="char">19.5 (14, 25)</td><td align="char">16 (11.5, 23.5)</td><td align="char">18 (13.3, 26.5)</td><td align="char">19 (14, 29)</td><td align="char">18 (15, 23)</td><td align="char">18.5 (14, 23)</td></tr></tbody></table><table-wrap-foot><fn><p>Values are given as median (IQR).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn0025"><label>a</label><p><italic>p</italic>&#x000a0;=&#x000a0;0.08.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn0030"><label>b</label><p><italic>p</italic>&#x000a0;=&#x000a0;0.06.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn0035"><label>c</label><p><italic>p</italic>&#x000a0;=&#x000a0;0.08.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl0020" position="float"><label>Table 4</label><caption><p>Adverse events during the first 8 weeks after vaccination.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th colspan="5" align="left">Vaccine group (83 events)<hr/></th><th colspan="5" align="left">Control group (72 events)<hr/></th></tr><tr><th align="left"/><th align="left"/><th colspan="4" align="left">Grade<hr/></th><th align="left"/><th colspan="4" align="left">Grade<hr/></th></tr><tr><th align="left"/><th align="left">Total</th><th align="left">1</th><th align="left">2</th><th align="left">3</th><th align="left">4</th><th align="left">Total</th><th align="left">1</th><th align="left">2</th><th align="left">3</th><th align="left">4</th></tr></thead><tbody><tr><td colspan="11" align="left">Systemic</td></tr><tr><td align="left">Upper respiratory tract infection</td><td align="char"><bold>22</bold></td><td align="char">20</td><td align="char">1</td><td align="char">1</td><td align="char">0</td><td align="char"><bold>16</bold></td><td align="char">16</td><td align="char">0</td><td align="char">0</td><td align="char">0</td></tr><tr><td align="left">Gastroenteritis</td><td align="char"><bold>8</bold></td><td align="char">6</td><td align="char">0</td><td align="char">2</td><td align="char">0</td><td align="char"><bold>6</bold></td><td align="char">6</td><td align="char">0</td><td align="char">0</td><td align="char">0</td></tr><tr><td align="left">Conjunctivitis</td><td align="char"><bold>3</bold></td><td align="char">3</td><td align="char">0</td><td align="char">0</td><td align="char">0</td><td align="char"><bold>2</bold></td><td align="char">2</td><td align="char">0</td><td align="char">0</td><td align="char">0</td></tr><tr><td align="left">Cough</td><td align="char"><bold>4</bold></td><td align="char">4</td><td align="char">0</td><td align="char">0</td><td align="char">0</td><td align="char"><bold>0</bold></td><td align="char">0</td><td align="char">0</td><td align="char">0</td><td align="char">0</td></tr><tr><td align="left">Fungal skin rash</td><td align="char"><bold>2</bold></td><td align="char">2</td><td align="char">0</td><td align="char">0</td><td align="char">0</td><td align="char"><bold>1</bold></td><td align="char">1</td><td align="char">0</td><td align="char">0</td><td align="char">0</td></tr><tr><td align="left">Fever</td><td align="char"><bold>2</bold></td><td align="char">2</td><td align="char">0</td><td align="char">0</td><td align="char">0</td><td align="char"><bold>1</bold></td><td align="char">1</td><td align="char">0</td><td align="char">0</td><td align="char">0</td></tr><tr><td align="left">Pneumonia</td><td align="char"><bold>1</bold></td><td align="char">0</td><td align="char">1</td><td align="char">0</td><td align="char">0</td><td align="char"><bold>1</bold></td><td align="char">0</td><td align="char">0</td><td align="char">1</td><td align="char">0</td></tr><tr><td align="left">Rash</td><td align="char"><bold>3</bold></td><td align="char">3</td><td align="char">0</td><td align="char">0</td><td align="char">0</td><td align="char"><bold>0</bold></td><td align="char">0</td><td align="char">0</td><td align="char">0</td><td align="char">0</td></tr><tr><td align="left">Otitis media</td><td align="char"><bold>0</bold></td><td align="char">0</td><td align="char">0</td><td align="char">0</td><td align="char">0</td><td align="char"><bold>1</bold></td><td align="char">1</td><td align="char">0</td><td align="char">0</td><td align="char">0</td></tr><tr><td align="left">Septicemia</td><td align="char"><bold>1</bold></td><td align="char">0</td><td align="char">0</td><td align="char">1</td><td align="char">0</td><td align="char"><bold>0</bold></td><td align="char">0</td><td align="char">0</td><td align="char">0</td><td align="char">0</td></tr><tr><td align="left">Eczema</td><td align="char"><bold>0</bold></td><td align="char">0</td><td align="char">0</td><td align="char">0</td><td align="char">0</td><td align="char"><bold>1</bold></td><td align="char">1</td><td align="char">0</td><td align="char">0</td><td align="char">0</td></tr><tr><td align="left">Abscess</td><td align="char"><bold>0</bold></td><td align="char">0</td><td align="char">0</td><td align="char">0</td><td align="char">0</td><td align="char"><bold>1</bold></td><td align="char">0</td><td align="char">1</td><td align="char">0</td><td align="char">0</td></tr><tr><td align="left">Colic</td><td align="char"><bold>0</bold></td><td align="char">0</td><td align="char">0</td><td align="char">0</td><td align="char">0</td><td align="char"><bold>1</bold></td><td align="char">1</td><td align="char">0</td><td align="char">0</td><td align="char">0</td></tr><tr><td align="left">Depressed skull fracture</td><td align="char"><bold>1</bold></td><td align="char">0</td><td align="char">0</td><td align="char">1</td><td align="char">0</td><td align="char"><bold>0</bold></td><td align="char">0</td><td align="char">0</td><td align="char">0</td><td align="char">0</td></tr><tr><td align="left">Constipation</td><td align="char"><bold>0</bold></td><td align="char">0</td><td align="char">0</td><td align="char">0</td><td align="char">0</td><td align="char"><bold>1</bold></td><td align="char">1</td><td align="char">0</td><td align="char">0</td><td align="char">0</td></tr><tr><td colspan="11" align="char">Laboratory</td></tr><tr><td align="left">Elevated creatinine</td><td align="char"><bold>17</bold></td><td align="char">15</td><td align="char">2</td><td align="char">0</td><td align="char">0</td><td align="char"><bold>16</bold></td><td align="char">13</td><td align="char">3</td><td align="char">0</td><td align="char">0</td></tr><tr><td align="left">Neutropenia</td><td align="char"><bold>12</bold></td><td align="char">6</td><td align="char">6</td><td align="char">0</td><td align="char">0</td><td align="char"><bold>12</bold></td><td align="char">6</td><td align="char">4</td><td align="char">1</td><td align="char">1</td></tr><tr><td align="left">Anemia</td><td align="char"><bold>7</bold></td><td align="char">6</td><td align="char">1</td><td align="char">0</td><td align="char">0</td><td align="char"><bold>12</bold></td><td align="char">7</td><td align="char">5</td><td align="char">0</td><td align="char">0</td></tr></tbody></table></table-wrap><table-wrap id="tbl0025" position="float"><label>Table 5</label><caption><p>Antibody titres elicited by childhood vaccines one week post-vaccination.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">EPI vaccine</th><th align="left">Protective antibody level</th><th align="left">Control week 21 median (min, max) <italic>n</italic>/total (%)</th><th align="left">Vaccine week 21 median (min, max) <italic>n</italic>/total (%)</th><th align="left"><italic>p</italic>&#x02014;Difference between vaccine and control arm</th></tr></thead><tbody><tr><td align="left">Poliovirus</td><td align="left">&#x02265;1:8</td><td align="char">1024 (64, 1024)</td><td align="char">1024 (128, 1024)</td><td align="char">0.26</td></tr><tr><td align="left">HBsAg (mIU&#x000a0;ml<sup>&#x02212;1</sup>)</td><td align="left">&#x02265;10</td><td align="char">55.0 (10, 1000)</td><td align="char">27.0 (10, 1000)</td><td align="char">0.32</td></tr><tr><td align="left">HBV protective levels</td><td/><td align="char">24/26 (92%)</td><td align="char">17/24 (71%)</td><td align="char">0.05</td></tr><tr><td align="left">Dtx (IU&#x000a0;ml<sup>&#x02212;1</sup>)</td><td align="left">&#x02265;0.01</td><td align="char">0.8 (0.08, 5.3)</td><td align="char">0.8 (0.03, 3.5)</td><td align="char">0.25</td></tr><tr><td align="left">Ttx (IU&#x000a0;ml<sup>&#x02212;1</sup>)</td><td align="left">&#x02265;0.01</td><td align="char">3.2 (0.76, 9.0)</td><td align="char">2.7 (0.16, 9.2)</td><td align="char">0.35</td></tr><tr><td align="left">Hib (&#x003bc;g&#x000a0;ml<sup>&#x02212;1</sup>)</td><td align="left">&#x02265;0.15</td><td align="char">6.4 (0.13, 190.3)</td><td align="char">3.0 (0.08, 50.2)</td><td align="char">0.29</td></tr><tr><td align="left">Hib protective levels</td><td/><td align="char">25/26 (92%)</td><td align="char">25/27 (93%)</td><td align="char">0.51</td></tr><tr><td align="left">Ptx (IU&#x000a0;ml<sup>&#x02212;1</sup>)</td><td align="left">Unknown</td><td align="char">39 (1, 437)</td><td align="char">48 (1, 654)</td><td align="char">0.96</td></tr></tbody></table></table-wrap></floats-group></article>